Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer

Key Facts

Congruence Therapeutics, a leading computationally-driven biotechnology company developing a pipeline of novel small molecules for diseases with significant unmet medical need, announced today the appointment of Frank Taffy, JD as Chief Business Officer.
Mr. Taffy most recently served as Senior Vice President, Head of Business Development, and Board Representative at Schrödinger, Inc. where he led the entire spectrum of business development activities and consummated multiple collaboration agreements with large pharmaceutical and biotechnology companies.
In his new role, Mr. Taffy will lead the Company's corporate and business development and strategy functions, and along with other members of the executive team, assume responsibility for the next phase of growth of the Company as Congruence advances its pipeline of small molecule correctors toward the clinic.
"Congruence is establishing itself as a leader in the field of AI/ML enabled computational drug discovery, building a diverse pipeline of novel small molecule correctors for a wide range of indications, including genetic obesity, Parkinson's disease, and inflammatory conditions," commented Mr. Taffy.